Detailed Narrative
Robust Financial Performance in Q2 and H1 FY26
Anlon Healthcare demonstrated strong financial growth in Q2 FY26, with total income reaching INR 52.32 crore, marking a 116% year-on-year increase from INR 24.21 crore in Q2 FY25. EBITDA for the quarter grew 82% to INR 13.77 crore, and PAT surged nearly fourfold to INR 9.32 crore. For the first half of FY26, total income rose 38% to INR 85.53 crore, and PAT more than doubled to INR 12.86 crore, driven by consistent contribution from high-value intermediates and APIs.
Aggressive Capacity Expansion and Inorganic Growth Strategy
The company is pursuing a significant capacity expansion plan, including a 700 metric ton per year greenfield facility, which will increase total capacity to 1100 metric tons. Commissioning for this facility is set to begin within the current quarter and is expected to be completed in 16-18 months. Additionally, Anlon is actively exploring inorganic acquisitions, with an outcome anticipated by mid-next month, to further boost capacity by over 1100 metric tons and capitalize on existing order visibility.
Strategic Focus on High-Margin APIs and Global Market Penetration
Anlon aims to achieve a 30%+ revenue CAGR over the next three years by expanding into global markets and strengthening its portfolio of high-margin APIs. The company has secured Anvisa approval for its manufacturing facility, filed 21 DMFs, and plans upcoming submissions for ketoprofen in the USA and dexketoprofen trometamol in European countries. Commercialization of CDMO projects is scheduled for Q3 FY27, marking the company's entry into the high-value global CDMO space.
Prudent Funding and Debt-Free Ambition
The planned capital expenditure for the 700 metric ton expansion (INR 32 crore for FY27) and the inorganic acquisition (INR 50-55 crore) will be entirely funded through IPO proceeds and internal accruals, with no new debt planned. Management stated a clear objective to become debt-free by Q3 FY27, with current term loan debt standing at approximately INR 4.5 crore, demonstrating a commitment to a strong financial position.
Evolving Product Mix and Enhanced Export Focus
While H1 FY26 saw a product mix of approximately 70% APIs and 27.2% intermediates, the company is strategically adjusting its portfolio. Anlon is targeting to close FY26 with around 30% export revenue, with an ambitious goal to increase this to 60% in FY27. This export push is driven by a significant margin advantage, with export products yielding 15-17% higher EBITDA margins compared to domestic sales.
Operational Efficiency and Supply Chain Resilience
The Rajkot manufacturing facility operates at 84% capacity utilization, supported by a strong quality system and in-house R&D. Anlon maintains a fully backward integrated supply chain, with no direct KSM imports from China, primarily sourcing solvents and reagents from domestic importers. This strategy, coupled with continuous process optimization, aims to reduce dependency risks and enhance competitiveness.
Long-Term Revenue Outlook and Regulatory Compliance
With the full operationalization of its existing facility, new greenfield expansion, and inorganic acquisition, Anlon projects a total capacity of 1800-1900 metric tons. The company anticipates achieving an average revenue of INR 520-540 crore by FY27/28. Anlon is also progressing on regulatory fronts, expecting EU compliance by the end of this year and leveraging a customer to trigger a USFDA audit in June 2026.